Allograft will lead bone grafts and substitutes sales through 2036 with 62.0% of the material type segment in 2026. The market was valued at USD 3.46 billion in 2025 and is expected to be worth USD 4.85 billion by 2036, creating an incremental opportunity of USD 1.28 billion.